Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Menorrhagia, Abnormal bleeding tendency (abnormal bleeding), Impaired collagen-induced platelet aggregation, and Bruising susceptibility and others; and very common findings: Impaired clot retraction. 13 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Blood and immune system | 9 | Abnormal bleeding tendency (abnormal bleeding), Prolonged bleeding time, Impaired ristocetin-induced platelet aggregation |
ITGB3 encodes integrin subunit beta 3 (788 aa). Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Highest expression in Artery Aorta (59.1 TPM) and Thyroid (48.5 TPM).
Glanzmann thrombasthenia 2 is associated with mutations in the ITGB3 gene on chromosome 17.
ITGB3 is classified as a druggable target (Cell Surface, Druggable Genome, and External Side Of Plasma Membrane categories) with score 3.5.
Genetic testing for ITGB3 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for Glanzmann thrombasthenia 2 has been reported in the published literature.
Phenotype severity distribution: 6 always present features, 1 very common feature, 1 common feature.
No clinical trials have been registered for Glanzmann thrombasthenia 2.
44 publications have been identified in PubMed for Glanzmann thrombasthenia 2. Research spans Case Report / Case Series (30%), Epidemiology / Natural History (27%), and Diagnostic / Biomarker (16%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 13 | 30% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 6:53 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Common questions about Glanzmann thrombasthenia 2
12 |
27% |
Testing and diagnosis research | 7 | 16% |
Laboratory research | 7 | 16% |
Research summaries | 4 | 9% |
New treatment approaches | 1 | 2% |
Shanmugam B (2026). [PMID: 41728151](https://pubmed.ncbi.nlm.nih.gov/41728151/). *Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion*. [Epidemiology / Natural History]
Güleser ÜY (2026). [PMID: 41796935](https://pubmed.ncbi.nlm.nih.gov/41796935/). *J AAPOS*. [Case Report / Case Series]
Glonnegger H (2026). [PMID: 42082146](https://pubmed.ncbi.nlm.nih.gov/42082146/). *Hamostaseologie*. [Diagnostic / Biomarker]
Zibara V (2026). [PMID: 41874099](https://pubmed.ncbi.nlm.nih.gov/41874099/). *Hematol Rep*. [Review / Meta-Analysis]
Mohammad Alizade T (2026). [PMID: 41591555](https://pubmed.ncbi.nlm.nih.gov/41591555/). *Annals of hematology*. [Case Report / Case Series]
El-Ghamrawy M (2026). [PMID: 42039087](https://pubmed.ncbi.nlm.nih.gov/42039087/). *J Blood Med*. [Epidemiology / Natural History]
Citla-Sridhar D (2026). [PMID: 42154520](https://pubmed.ncbi.nlm.nih.gov/42154520/). *J Pediatr Hematol Oncol*. [Epidemiology / Natural History]
Rutten KHG (2026). [PMID: 41403382](https://pubmed.ncbi.nlm.nih.gov/41403382/). *Haemophilia : the official journal of the World Federation of Hemophilia*. [Epidemiology / Natural History]
Zaninetti C (2026). [PMID: 41791656](https://pubmed.ncbi.nlm.nih.gov/41791656/). *Journal of thrombosis and haemostasis : JTH*. [Basic Science / Preclinical]
El-Sayed HA (2026). [PMID: 41728181](https://pubmed.ncbi.nlm.nih.gov/41728181/). *Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion*. [Case Report / Case Series]
AI-curated news mentioning Glanzmann thrombasthenia 2
Updated Apr 10, 2026
Hemab Therapeutics has filed for a $100 million IPO to advance its development of antibody-based therapies for blood coagulation disorders. The company is Phase 3-ready for its lead candidate, sutacimig (HMB-001), targeting Glanzmann thrombasthenia and Factor VII deficiency.